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Fibroblast growth factor- (FGF-)23 is a recently discovered regulator of calcium-phosphate metabolism. FGF-23 appears to
decrease in synthesis and accelerated degradation of 1,25(OH)2D. Together with its cofactor Klotho, FGF-23 maintains serum
phosphate levels within the normal range by increasing renal phosphate excretion. In chronic kidney disease (CKD), FGF-23 levels
rise in parallel with the decline in renal function long before a signiﬁcant increase in serum phosphate concentration occurs.
Both Klotho and FGF-23, linked by a receptor mechanism, aﬀect vitamin D synthesis and parathyroid hormone (PTH) secretion.
Previous studies have shown a close association between reduced FGF-23 or Klotho activities and vascular calciﬁcation. The
possible association of FGF-23 and left ventricular hypertrophy or vascular dysfunction has been proposed. Finally, prospective
studies have shown that high serum FGF-23 concentrations predict more rapid disease progression in CKD patients who were
not on dialysis and increased mortality in patients on maintenance hemodialysis. FGF-23 may therefore prove to be an important
therapeutic target for the management of CKD.
1.Introduction
Fibroblast growth factor- (FGF-) 23 is recently discovered
and is involved in the control of phosphate (P) and calcium
(Ca) metabolism [1]. FGF-23 is a 251-amino acid protein
(molecular weight; 26kDa) that is synthesized and secreted
by bone cells, mainly osteoblasts [2]. It is composed of an
amino-terminal signal peptide (residues 1–24), an “FGF-
like sequence” (residues 25–180), and a carboxyl-terminal
extended sequence (residues 181–251), which is unique
among members of the FGF family [3]. Since FGF-23 has
low aﬃnity for heparin, it can be distributed throughout the
body in the blood and mediates its systemic function [4].
The biological activity and physiological role of FGF-
23 in P and vitamin D metabolism in vivo have recently
been clariﬁed. Several animal models with excess FGF-
23 activity as a result of in vivo forced overexpression
exhibit hypophosphatemia and increased P excretion of
1,25-dihydroxyvitamin D [1,25(OH)2D] [5–8], and Fgf23
knockout (KO) mice are characterized by increased renal P
reabsorption and an elevated serum 1,25(OH)2Dc o n c e n -
tration [9, 10]. FGF-23 appears to impair the synthesis and
accelerate the degradation of 1,25(OH)2D, because expres-
sion of renal 25-hydroxyvitamin D-1α-hydroxylase mRNA
changes within 1h after injecting mice with recombinant
FGF-23 [11]. The increased degradation of 1,25(OH)2Db y
24-hydroxylase may be associated. RecombinantFGF-23 also
has a phosphaturic eﬀect, which is attributable to reduced
renal P reabsorption. FGF-23 down-regulates the expression
of both type IIa and type IIc sodium-P cotransporters on the
apicalsurfaceofrenalproximaltubularepithelialcellsinvivo
[11, 12].
2. Measurement of Serum FGF-23 Levels
The half-life of intact FGF-23 in the circulation of healthy
individuals has been estimated to be 58min [13]. Two
assays for measurement of human FGF-23 are commercially
available. One is a sandwich enzyme-linked immunosorbent
assay for measurement of full-length FGF-23 that uses
diﬀerent monoclonal antibodies to detect the simultaneous
presence of both the N-terminal [14] and C-terminal [15]
portions of FGF-23. The other assay is a C-terminal assay2 International Journal of Nephrology
that recognizes both full-length and processed (presum-
ably inactive) C-terminal fragments of FGF-23. The intra-
assay variability of the C-terminal FGF-23 assay is 5% at
52.7RU/ml and 7.2% at 140.0RU/ml, whereas interassay
variability is 5% at 50.9RU/ml and 7.3% at 153.0RU/ml.
The lower limit of detection is 3.0RU/ml. The intra-assay
variability of the intact FGF-23 assay is 4.4% at 14.6pg/ml
and 2.6% at 148.0pg/ml, and its interassay variability is
6.1% at 15.6pg/ml and 6.5% at 166.0pg/ml. The lower limit
of detection is 1.0pg/ml (according to the manufacturer’s
speciﬁcations).
3. InteractionbetweenFGF-23 andKlotho
Klotho is a 130-kDa transmembrane β-glucuronidase that
catalyzes the hydrolysis of steroid β-glucuronides and was
discovered by Kuro-o et al. in 1997 [16]. The Klotho
gene is expressed in a limited number of tissues, mainly
the kidneys, and mutations cause multiple aging-related
disorders in nearly all organs and tissues [17]. Because
FGF-23-KO mice exhibit phenotypes similar to those of
Klotho-KO mice [18, 19], a common signaling pathway has
been postulated. Indeed, FGF-23 exerts its biological eﬀects
through activation of FGF receptors (FGF-Rs) in a Klotho-
dependent manner, because a Klotho/FGF-R complex binds
to FGF-23 with higher aﬃnity than FGF-R or Klotho alone
[20].FGF-23hasratherlowaﬃnityforitswidelyrepresented
receptors and the presence of circulating Klotho is essential
to facilitate the binding of FGF-23 to its receptors [21]. Thus,
activation of FGF-23 receptors requires not only presence
of the circulating FGF-23 as their ligand, but the presence
of Klotho as a speciﬁc promoter whose aﬃnity dictates the
selectivity on its targets.
Klotho is mainly expressed in the kidneys, whereas FGF-
23 comes from bone cells, and this functional bone-kidney
axis is of physiological and pathological relevance. Based on
available knowledge, this axis seems to exert a prevailing
regulation of Ca balance with Klotho and to exert a more
speciﬁc and direct eﬀect on P homeostasis through FGF-23.
Both Klotho and FGF-23, linked by the receptor mechanism
described above, aﬀect vitamin D synthesis and parathyroid
hormone (PTH) secretion, and both are expressed in the
parathyroid glands, suggesting that FGF-23 might regulate
PTH secretion. In support of this possibility, data obtained
in vitro suggest that FGF-23 decreases PTH mRNA tran-
scription and protein secretion in a dose-dependent manner
[22]. Conversely, PTH may stimulate FGF-23 secretion
by osteoblasts, because the FGF-23 levels of rodents with
primary hyperparathyroidism (HPT) are increased, which
may be reduced by parathyroidectomy [23].
4. Role of FGF-23 inChronicKidney
Disease(CKD)
Patients with stages 3–5 CKD and dialysis patients often
develop hyperphosphatemia due to impaired renal P excre-
tion. Decreased 1,25(OH)2D production interferes with
this process. The decrease in vitamin D activation induces
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Figure 1: Serum ﬁbroblast growth factor (FGF)-23 levels are
negatively associated with estimated glomerular ﬁltration rates.
Cited from the J Am Soc Nephrol 2005; 16: 2205–15 by Guti´ errez
et al. [24].
hypocalcemia and a subsequent increase in PTH secretion to
maintain serum Ca levels normal but induces a high level of
bone turnover and hyperphosphatemia [25].
It has been reported that serum FGF-23 levels increased
as renal function declines [26, 27]; circulating FGF-23 levels
ofCKDpatientsgraduallyincreasewithdecliningrenalfunc-
tion (Figure 1)[ 24]. It has been therefore hypothesized that
the increased FGF-23 levels in CKD are primarily the result
of decreased renal clearance [28]. By contrast, no association
between FGF-23 levels and glomerular ﬁltration rate has
been found in the earlier stages of CKD, when patients
arenormophosphatemic[28].Thehyperphosphatemiaasso-
ciated with CKD most likely triggers FGF-23 production,
which promotes renal phosphate excretion, reﬂected by the
severely elevated FGF-23 levels in CKD subjects. In studies of
healthy subjects exposed to an increased or decreased P load,
conﬂicting results regarding a correlation between FGF23
and serum P levels have been shown.
The cause of the increased FGF-23 levels in CKD
patients is still under investigation. Instead of decreased
renal clearance, there may be end-organ resistance to the
phosphaturic action of FGF-23 because of a deﬁciency of
the required Klotho cofactor. Koh et al. reported signiﬁ-
cantly reduced Klotho mRNA expression in kidney biopsy
specimens of CKD patients [29]. The higher FGF-23 levels
in CKD patients may reﬂect a physiological compensation
that stabilizes serum P levels as the number of intact
nephrons declines. FGF-23 increases urinary P excretion
and decreases gastrointestinal P absorption both directly
and indirectly by inhibiting 1α-hydroxylase and reducing
circulating 1,25(OH)2Dl e v e l s[ 30].
Since FGF23 has a profound eﬀect on down-regulating
renal expression of the 1α-hydroxylase, excess FGF23 in
vivo may signal via parathyroid cells an increase in PTH
production, as a part of a counter-regulatory feedback loop
to protect the decrease in vitamin D and Ca levels. There
are in vivo animal models of FGF-23 overexpression, and
all of them are characterized by parathyroid hyperplasia andInternational Journal of Nephrology 3
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Figure 2: Proposed model for the eﬀects of elevated Ca and P on vascular smooth muscle cell (SMC) matrix mineralization. Cited from the
J Am Soc Nephrol 2004; 15: 2959–164 by Giachelli [31].
increased PTH levels [32]. A more likely scenario is that the
increase in PTH levels and parathyroid hyperplasia observed
in these animals is mediated by the Ca-sensing receptor,
again protecting systemic Ca levels, because the suppressed
1,25(OH)2D levels would lead to persistent hypocalcemia.
Indeed, mice expressing high systemic levels of FGF-23
(R176Q) exhibit hypocalcemia and subsequent development
of secondary HPT, even though their elevated PTH levels are
likely to aggravate the prevailing hypophosphatemia [33].
5. FGF-23and VascularCalciﬁcation
CKD patients have dramatically higher cardiovascular mor-
bidity and mortality rates than the general population [34].
In the last 10 years, several studies have pointed to vascular
calciﬁcation as a major cause of cardiovascular disease
in the dialysis population [35–39]. CKD patients develop
extensivemedialcalciﬁcation,whichcausesincreasedarterial
stiﬀness and high morbidity and mortality due to cardiovas-
cular events [40]. Vascular calciﬁcation alters the pulsatile
dynamics and thereby contributes to an increase in left
ventricular load, and it is the most important contributor to
the development of left ventricular hypertrophy in patients
undergoing hemodialysis [41]. A variety of risk factors are
associated with vascular calciﬁcation in dialysis patients
(dialysis vintage, uremic toxins, history of diabetes, inﬂam-
mation),butabnormalities inbonemineralmetabolism may
play a critical role [42]. In fact, elevated serum P and PTH
levelscontributetovascularcalciﬁcation,althoughtheirroles
are incompletely understood. Elevated serum P levels may
worsen cardiovascular events in the uremic population by
progressively increasing calcium deposition in the coronary
arteries and heart valves [43].
Jono et al. showed that elevated P levels (>2.4mM)
induce smooth muscle cell (SMC) calciﬁcation in vitro [44].
P transport into cells from the extracellular compartment
is primarily mediated by membrane transporters called
sodium-dependent P cotransporters, and a type III sodium-
dependent P cotransporter, Pit-1, has been found to be
associated with SMC calciﬁcation [45]. Likewise, increasing
the Ca levels in culture media to levels that are considered
hypercalcemic (>2.6mM) leads to increased mineralization
and phenotypic transition of SMCs [46]. Elevated Ca-
induced mineralization is also dependent on Pit-1. Figure 2
depicts the mechanism of vascular calciﬁcation as a result of
transformation of SMC to osteoblast-like cells [31].
Both human and animal studies have shown a close
association between reduced FGF-23 or Klotho activities
and vascular calciﬁcation. Extensive vascular calciﬁcation is
observed in Fgf23-KO mice by 6 weeks of age [47], inter-
estingly, expression of the sodium-P cotransporter NaPi2a
by their proximal tubular epithelial cells is upregulated.
Moreover, the bone mineral density (BMD) of Fgf23-
KO mice is strikingly reduced. Human studies have also
shown an association between reduced BMD and vascular
calciﬁcation [48], and low BMD has been suggested to
independently predict coronary artery in women, with a
higher odds ratio than traditional risk factors [49]. In view
of the phenotypes of both Fgf23- and Kloth-KO mice, it
seems likely that in vivo dysregulation of the FGF-23-Klotho
axis can lead to vascular calciﬁcation, possibly by aﬀecting
mineral ion metabolism [50].4 International Journal of Nephrology
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Figure 3: Association between serum FGF-23 levels and renal survival. Cited from the J Am Soc Nephrol 2007; 18: 2600–8 by Fliser et al.
[27].
6.FGF-23As a PrognosticFactorin
CKD Patients
Interest in FGF-23 increased tremendously after the publi-
cation of two prospective cohort studies in which FGF-23
was identiﬁed as a risk factor for a poorer outcome in CKD
patients. The ArMORR study revealed that high FGF-23
levels in patients starting hemodialysis were an independent
predictor of 1-year mortality after adjustment for serum P
levels [51], and in a multivariable adjusted model, subjects
whose FGF-23 levels were in the highest quartile had nearly
a sixfold increase in risk in mortality over the subjects in
the lowest quartile. Thus, FGF-23 was a much stronger
predictor of mortality than serum P levels. In the MMKD
trial [27], 227 patients with nondiabetic stages 1–4 CKD
were prospectively followed up for a median of 53 months
to assess the progression of renal disease. Among the various
parameters of Ca-P metabolism evaluated, FGF-23 levels
wereasigniﬁcantindependentpredictorofCKDprogression
(Figure 3), which was deﬁned as a doubling of the serum
creatinineleveland/orterminalrenalfailure.Again,theFGF-
23 levels were a better outcome predictor than the serum P
levels, and in a Cox regression analysis the P levels lost their
predictive value after adjusting for FGF-23.
Serum FGF-23 levels have been reported to be indepen-
dently related to aortic calciﬁcation index in hemodialysis
patients [52]. Jean et al. reported an association between
serum FGF-23 levels and increased mortality in long
hemodialysis patients [53]. Multivariate linear regressions
have shown a correlation between phosphatemia and serum
FGF-23 levels, conﬁrming the association between higher
serumFGF-23levelswithmortalityandvascularcalciﬁcation
regardless of the serum P levels. On the other hand, Inaba et
al. found that plasma FGF-23 level of both male nondiabetic
and diabetic hemodialysis patients is an independent factor
negatively associated with peripheral vascular calciﬁcation in
the hand artery, but not in aorta, even when adjusted for the
Ca x P product [54]. Thus, serum FGF-23 levels may provide
a reliable marker for Moenckeberg’s medial calciﬁcation in
male hemodialysis patients, independent of the regulatory
eﬀect of FGF-23 on P metabolism, followed by increased
mortality in these patients [55].
7. Conclusion andFutureProspects
FGF-23 is a recently discovered regulator of Ca and P
metabolism. Serum FGF-23 levels have been reported to
increase in the very early stages of CKD, and the increase
may represent a long-term, delayed response to transient
episodes of hyperphosphatemia occurring in the early stage
of CKD, possibly when the rapid response of PTH is
becoming insuﬃcient. Accordingly, both FGF-23 and PTH
are involved in the adaptive response to ensuing secondary
hyperparathyroidism, with the diﬀerence that PTH accentu-
ates the calcitriol deﬁciency but FGF-23 does not.
In clinical trials, elevated FGF-23 levels have been found
to be independently associated with more rapid pro-
gression of CKD, therapy-resistant secondary HPT [56],
and increased cardiovascular mortality in dialysis patients.
However, FGF-23 is not just an innocent bystander that
reﬂects unfavorable derangements of Ca-P metabolism (e.g.,
increased serum phosphate levels) in CKD, but a patho-
physiologically relevant factor. Thus, FGF-23 is a promising
candidate for a therapeutic target that might improve the
fatal prognosis of CKD patients. Since any increase in serum
P level seems to link between CKD and cardiovascular
disease, clinical interest in FGF-23 seems to be appropriate.International Journal of Nephrology 5
It has recently been reported that FGF-23 is inde-
pendently associated with left ventricular hypertrophy in
patients with CKD [57]. In addition, circulating FGF-23 has
been associated with vascular dysfunction in the community
[58]. Additional studies are required to determine possible
direct eﬀects on the left ventricle and vasculature. A recent
study that evaluated serum FGF-23 levels in a cohort
of patients starting dialysis found that its quartiles are
progressively and independently associated with mortality.
Moreover, FGF-23 may be a cause of 1,25(OH)2D insuf-
ﬁciency, and that could be a further link with increased
mortality,in view of theroleofvitaminDreceptor activation
that is claimed to exist in several disease conditions. Finally,
the functional interplay between FGF-23 and Klotho may
represent another link with mortality.
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